

### **REMARKS**

The specification has been amended to update the continuing data on page 1 and to remove reference to hyperlinks directed to Internet addresses.

#### ***Double Patenting Rejection***


Claims 1-5 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2, 17-28, 186-200, and 231-245 of U.S. Patent No. 6,346,655. Applicants have enclosed a terminal disclaimer in compliance with 37 C.F.R. § 1.321(c) to overcome this rejection. Thus, Applicants respectfully request that this rejection be withdrawn.

### **CONCLUSION**

In view of the above remarks and amendments, Applicants submit that this application is now ready for allowance. Notice to this effect is respectfully solicited. If the Examiner has any further concerns and believes a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned agent.

Respectfully submitted,

Syngenta Biotechnology, Inc.  
3054 Cornwallis Road  
Research Triangle Park, NC 27709  
Date: November 11, 2004

  
Gregory W. Warren  
Agent for Applicants  
Reg. No. 48,385  
Telephone: 919-541-8646